In postmenopausal receptor-positive breast cancer patients, the main drugs for adjuvant endocrine therapy are aromatase inhibitors, mainly including anastrozole, letrozole, and exemestane. The antitumor effects and toxic reactions of the above three drugs are basically similar, and the most appropriate aromatase inhibitor should be the one designed for the clinical trial in which it is enrolled and which is closest to the current clinical situation. The duration of endocrine therapy is not well established at this time, and clinical studies of tamoxifen adjuvant therapy with sequential aromatase inhibitors do not include such patients. Some women develop amenorrhea during tamoxifen therapy, but it is possible to restore ovarian function after stopping tamoxifen and starting treatment with aromatase inhibitors. Therefore, plasma estradiol and FSH levels can be tested regularly in clinical practice. If ovarian function is restored, treatment with aromatase inhibitors should be discontinued and replaced with tamoxifen, or aromatase inhibitors should be continued after measures have been taken to suppress ovarian function.